Pharmacyclics Reports First Quarter Fiscal 2009 Financi...(al development plans andproduct developm...)

Date:10/30/2008

al development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with our ability to obtain future financing and fund the product development of our pipeline; our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months; unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2008 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publi
'/>"/>

SOURCE Pharmacyclics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
2. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
3. Pharmacyclics Announces It Received Nasdaq Notification
4. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. United Therapeutics Reports Third Quarter 2008 Financial Results
8. BioMed Realty Trust Reports Third Quarter 2008 Financial Results
9. Varian, Inc. Reports Strong Fourth Quarter 2008 Results
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. VNUS Medical Technologies Reports Third-Quarter 2008 Results: 25% Growth in Net Product Revenues and 29% Growth in Unit Sales Over Third Quarter 2007